Grifols, S.A. (NASDAQ:GRFS) Shares Bought by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. lifted its position in Grifols, S.A. (NASDAQ:GRFS) by 5.0% during the third quarter, Holdings Channel reports. The institutional investor owned 58,677 shares of the biotechnology company’s stock after buying an additional 2,790 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Grifols were worth $521,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. GAMMA Investing LLC raised its position in Grifols by 49.4% in the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 1,135 shares in the last quarter. NBC Securities Inc. grew its stake in shares of Grifols by 2.8% in the 3rd quarter. NBC Securities Inc. now owns 52,181 shares of the biotechnology company’s stock worth $463,000 after purchasing an additional 1,433 shares during the last quarter. Signaturefd LLC raised its holdings in shares of Grifols by 66.2% in the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 2,153 shares in the last quarter. US Bancorp DE lifted its stake in Grifols by 12.3% during the third quarter. US Bancorp DE now owns 20,663 shares of the biotechnology company’s stock valued at $183,000 after purchasing an additional 2,256 shares during the last quarter. Finally, Creative Planning lifted its stake in Grifols by 26.4% during the third quarter. Creative Planning now owns 17,319 shares of the biotechnology company’s stock valued at $154,000 after purchasing an additional 3,614 shares during the last quarter.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank raised Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

Grifols Trading Down 8.2 %

NASDAQ:GRFS opened at $8.46 on Wednesday. The stock has a fifty day simple moving average of $8.88 and a 200 day simple moving average of $8.04. Grifols, S.A. has a 1-year low of $5.30 and a 1-year high of $12.15. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.